DiaMedica Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• DiaMedica Therapeutics Inc DMAC.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of four analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -19 cents to -17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• DiaMedica Therapeutics Inc's reported EPS for the quarter was a loss of 18 cents​.

• The company reported a quarterly loss of $7.71 million.

• DiaMedica Therapeutics Inc shares had risen by 0.9% this quarter and lost 29.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 10% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $10.50

This summary was machine generated from LSEG data May 13 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)